宿主导向抗菌药物的研究进展

Progress on Host-acting Antibacterial Drugs

细菌性感染疾病对人类和畜禽健康均造成巨大的威胁,病原菌耐药性和不明机制病原菌感染是抗菌药物研发的主要阻力。高效、新型抗菌药物仍将是治疗多重耐药菌和未知病原菌感染的最有效策略。宿主导向抗菌药物(host-acting antibacterial drugs,HADs)的发现与开发是抗菌感染领域新药研发的新趋势和热点,可以通过对宿主和病原菌相互作用机制的揭示寻找潜在的药物靶点和/或制定宿主导向的抗菌治疗方案。本文概述了宿主导向抗菌药物的研发进展,主要从减弱病原菌与宿主相互作用,直接促进宿主抗菌和协助宿主抗菌共三个方面展开讨论,着重强调宿主导向的抗菌药物研发策略,以期为抗菌药物研发提供新思路。

Bacterial infections have critical impact on both human and animal health.Particularly,emergence and dissemination of antibiotic resistance have paralyzed our public health systems.Antibiotic resistance and bacterial infections with unknown mechanisms are diminishing the discovery and development of new antibacterial drugs.Nevertheless,novel and efficacious antimicrobial agents remain the most effective strategy for the treatment of multi-drug resistant and unknown infections associated with pathogenic bacteria.There is an urgent and unmet demand to develop new antibacterial drugs with distinct modes of action to circuit such dilemma.Recently,the advance of host-acting antibacterial drugs(HADs)offers alternative prospect of more effective therapies against bacterial infections through the understanding of bacterial-host interactions,facilitating the identifi cation of novel and potential targets and host oriented rational use of drugs.In this review,we briefl y summarized the development of host-acting antibacterial drugs including moderation of bacterial-host interactions,promotion and assistance of antibacterial activities in hosts to shed light on the development of alternative strategies to treat bacterial infections in clinic.